Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term rituximab. Found 12 abstracts

Schmier J, Ogden K, Nickman N, Halpern MT, Cifaldi M, Ganguli A, Bao Y, Garg V. Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting. Clinical therapeutics. 2017 Aug;39(8):1600-17.
Barta SK, Li H, Hochster HS, Hong F, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Colocci N, Bengtson EM, Horning SJ, Kahl BS. Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer. 2016 Jun 28;122(19):2996-3004.   PMCID: 5030179
Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA. Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Oct;10(10):1211-9.   PMCID: not NIH funded
Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, Carpenter SP, Allan BW, Nelson JG, Slapak CA, Smith MR, Link BK, Wooldridge JE, Ganjoo KN. Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in Fc gamma RIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma. Clinical Cancer Research. 2012 Mar;18(5):1395-403.   PMCID: not NIH funded
LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012 Mar;119(9):2093-9.   PMCID: not NIH funded
Weiss RF, Miller MG, Cronin JF, Hensley HH, Joshi ID, Smith MR. Parametric Model of Combination Therapy for Non-Hodgkin Lymphoma. Plos One. 2012 Dec;7(12):e51736.   PMCID: PMC 3522695
Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD, Bolwell BJ, Freytes CO, Gale RP, Goldstein SC, Hale GA, Inwards DJ, Klumpp TR, Marks DI, Maziarz RT, McCarthy PL, Pavlovsky S, Rizzo JD, Shea TC, Schouten HC, Slavin S, Winter JN, van Besien K, Vose JM, Hari PN. A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR. Biology of Blood and Marrow Transplantation. 2010 Jan;16(1):35-45.   PMCID: PMC2929576
Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. British Journal of Haematology. 2008 Nov;143(3):355-60.
Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature. Leukemia & lymphoma. 2006 Sep;47(9):1902-7.
Smith MR, Joshi I, Jin F, Obasaju C. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice. BMC cancer. 2005 Aug 18;5:Art.
Ansell SM, Schilder RJ, Pieslor PC, Gordon LI, Emmanouilides C, Vo K, Czuczman MS, Witzig TE, Theuer C, Molina A. Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: A review of the literature. Clinical Lymphoma. 2004 Dec;5(3):202-4.
Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DH, Berlfein JR, Ding E, Grillo-Lopezs AJ. Phase I/II Y-90-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC- Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. European Journal of Nuclear Medicine. 2000 Jul;27(7):766-77.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term rituximab

rituximab lymphoma ANTI-CD20 MONOCLONAL-ANTIBODY trial therapy non-Hodgkin lymphoma radioimmunotherapy survival non-Hodgkin's lymphoma cisplatin immunochemotherapy drug therapy THERAPY chop 2nd international workshop group transplantation therapeutic use SYSTEMIC THERAPY m(2) once every 2-3 months Objective maintenance Infliximab arthritis bcl-2 antisense oligonucleotides complementary administration & dosage b-cell PATTERN elderly-patients Home Infusion Therapy either primary CBCL or low-grade effective in treating of CBCL Allogeneic transplantation use infliximab remission One patient received local radiotherapy to a solitary lymphomas with relapses limited to the skin Rituximab appears to non-hodgkins-lymphoma mouse model efficacy european mcl network idec-c2b8 treatment strategies B cell chemotherapy oblimersen sodium IDEC-Y2B8 transcript Abatacept EORTC CLASSIFICATION dosimetry abatacept antibodies progression clinical responses occurred in all five patients Three patients have EFFICACY no recurrences of either grade CBCL immunoglobulin sequences therapeutic 90 Zevalin Rheumatoid Arthritis Economic Models rheumatoid superior phase-ii consensus panel recommendations macroglobulinemia clinical-trial prospective at age 87 years from a non-related cause after 55 years of complete yttrium rituximab maintenance immunoglobulin-m anti-cd20 monoclonal-antibody follicular lymphoma Antirheumatic Agents cutaneous high-dose chemotherapy indolent lymphoma CHOP CHEMOTHERAPY Hospital Costs intravenous infusions of 375 mg multicenter apoptosis Unrelated igm 1987 arlson me-journal of chronic diseases-v40-p373 randomized-trial united-states cancer cutaneous site of large-cell lymphoma that developed after 3 years in Intravenous Infusions Rituximab United States hospital costs FOLLICULAR-GROWTH DENDRITIC CELLS ELDERLY-PATIENTS c-receptor polymorphisms contraindicated or unwanted Additional collaborative studies are monoclonal follow-up low-grade single-agent recurrent B-cell NHL each with either extensive established We treated five patients with rituximab given as a single agent for four weekly therapy bone-marrow dosimetry 19 ongoing complete clinical remissions with a median follow-up of 17 remission from the low-grade CBCL present an attractive alternative when radiation therapy is chemotherapy plus CYTOTOXIC T-CELLS economics ofatumumab cytotoxic drugs antibody CYCLOPHOSPHAMIDE european was given at 375 mg initiated chronic lymphocytic-leukemia immunoglobulin fusion humanized dexamethasone follicular CHRONIC LYMPHOCYTIC-LEUKEMIA s-phase malignant-lymphoma have yet occurred Treatment was well tolerated Rituximab is safe and igg Monoclonal Antibodies-Humanized TUMOR BURDEN AB Optimal treatment of cutaneous B-cell lymphoma (CBCL) is yet to be weekly bortezomib mipi aggressive lymphoma and 39 months post achievement of complete remission One patient died PROTEIN EXPRESSION international prognostic index reduced-intensity progression-free survival if m(2) Maintenance therapy NON-HODGKINS-LYMPHOMA PROGNOSTIC-SIGNIFICANCE needed to assess the role of rituximab in various clinicopathologic severe comorbidities or who refused treatment with radiation lesions presentations of CBCL i-131 APOPTOSIS Hodgkin lymphoma bone-marrow-transplantation
Last updated on Wednesday, February 05, 2020